Potential new indications of topical calcineurin inhibitors

Dermatology

Volumn 215, Issue SUPPL. 1, 2007, Pages 45-54

  Luger, Thomas ^a   Paul, Carle ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Inflammatory skin diseases; Pimecrolimus; Topical calcineurin inhibitors

Indexed keywords

BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CLOBETASOL; CORTICOSTEROID; GAMMA INTERFERON; HYDROCORTISONE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; PIMECROLIMUS; TACROLIMUS; TRANSCRIPTION FACTOR NFAT;

ALOPECIA AREATA; APPLICATION SITE BURNING; APPLICATION SITE PRURITUS; BULLOUS SKIN DISEASE; CONTACT DERMATITIS; CROHN DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FACE; GENITAL MALFORMATION; GRAFT VERSUS HOST REACTION; GRANULOMA ANNULARE; HAILEY HAILEY DISEASE; HAND ECZEMA; HUMAN; LANGERHANS CELL; LICHEN PLANUS; LYMPHOCYTOMA; MYCOSIS; NECK; NECROBIOSIS LIPOIDICA; NETHERTON DISEASE; PRIORITY JOURNAL; PSORIASIS; PYODERMA GANGRENOSUM; REVIEW; SARCOIDOSIS; SEBORRHEIC DERMATITIS; SKIN INFLAMMATION; SKIN LUPUS ERYTHEMATOSUS; STAPHYLOCOCCUS INFECTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; URTICARIA; UVEITIS; VITILIGO;

ADMINISTRATION, CUTANEOUS; CALCINEURIN; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; SKIN DISEASES; TACROLIMUS;

EID: 37349125327     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102119     Document Type: Review

References (117)

1. Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T, Christophers E, Kapp A, Lahfa M, Rubins A, Jablonska S, Rustin M: Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000;136:999-1006.
2. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Hultsch T, Graeber M, Cherill R, de Prost Y: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:1-8.
3. Paul C, Graeber M, Stuetz A: Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin Investig Drugs 2000;9:69-77.
4. Hoetzenecker W, Ecker R, Kopp T, Stuetz A, Stingl G, Elbe-Burger A: Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol 2005;115:1276-1283.
5. Hoetzenecker W, Meingassner JG, Ecker R, Stingl G, Stuetz A, Elbe-Burger A: Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004;122:673-684.
6. Meingassner JG, Kowalsky E, Schwendinger H, Elbe-Burger A, Stutz A: Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol 2003;149:853-857.
7. Panhans-Gross A, Novak N, Kraft S, Bieber T: Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001;107:345-352.
8. Wolff K: Pimecrolimus 1% cream for the treatment of atopic dermatitis. Skin Therapy Lett 2005;10:1-6.
9. Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Ruzicka T, Kind P, Dubertret L, Bos JD: Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 1998;134:1101-1102.
10. Mrowietz U, Wustlich S, Hoexter G, Graeber M, Brautigam M, Luger T: An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 2003;83:351-353.
11. Feldmann RJ, Maibach HI: Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol 1967;48:181-183.
12. Billich A, Aschauer H, Aszodi A, Stuetz A: Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004;269:29-35.
13. Allen BR, Lakhanpaul M, Morris A, Lateo S, Davies T, Scott G, Cardno M, Ebelin ME, Burtin P, Stephenson TJ: Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003;88:969-973.
14. Harper J, Green A, Scott G, Gruendl E, Dorobek B, Cardno M, Burtin P: First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001;144:781-787.
15. Alaiti S, Kang S, Fiedler VC, Ellis CN, Spurlin DV, Fader D, Ulyanov G, Gadgil SD, Tanase A, Lawrence I, Scotellaro P, Raye K, Bekersky I: Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol 1998;38:69-76.
16. Queille-Roussel C, Graeber M, Thurston M, Lachapelle JM, Decroix J, de Cuyper C, Ortonne JP: SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis 2000;42:349-350.
17. Saripalli YV, Gadzia JE, Belsito DV: Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis. J Am Acad Dermatol 2003;49:477-482.
18. McLean CJ, Lobo RF, Brazier DJ: Cataracts, glaucoma, and femoral avascular necrosis caused by topical corticosteroid ointment. Lancet 1995;345:330.
19. Amrol D, Keitel D, Hagaman D, Murray J: Topical pimecrolimus in the treatment of human allergic contact dermatitis. Ann Allergy Asthma Immunol 2003;91:563-566.
20. Belsito DV, Fowler JF Jr, Marks JG Jr, Pariser DM, Hanifin J, Duarte IA, Pires MC, Cruz PD Jr, Langley RG, Patel P, Bush C, Thurston M, Graeber M, Cherill R: Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis 2004;73:31-38.
21. Thaci D, Steinmeyer K, Ebelin ME, Scott G, Kaufmann R: Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology 2003;207:37-42.
22. Thelmo MC, Lang W, Brooke E, Osborne BE, McCarty MA, Jorizzo JL, Fleischer A, Jr: An open-label pilot study to evaluate the safety and efficacy of topically applied tacrolimus ointment for the treatment of hand and/or foot eczema. J Dermatol Treat 2003;14:136-140.
23. Diskin R, Del Rosso JQ, Schrieber S: Observational use of pimecrolimus 1% cream: Clinical results and applications based on a large private practice experience. J Am Osteopath Coll Dermatol 2004;1:39-41.
24. Schurmeyer-Horst F, Luger TA, Bohm M: Long-term efficacy of occlusive therapy with topical pithecrolithus in severe dyshidrosiform hand and foot eczema. Dermatology 2007;214:99-100.
25. Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB Jr: A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003;9:2.
26. Lebwohl M: Psoriasis. Lancet 2003;361:1197-1204.
27. Wong VK, Della Croce C, Schonfeld S, Mastrangelo AM, Lebwohl M: Use and abuse of topical corticosteroids in infections of the skin and related structures. J Drugs Dermatol 2003;2:268-276.
28. Freeman AK, Linowski GJ, Brady C, Lind L, Vanveldhuisen P, Singer G, Lebwohl M: Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003;48:564-568.
29. Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, Zaias N, Chen DM, Parneix-Spake A, Hultsch T, Menter A: Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004;51:731-738.
30. Yamamoto T, Nishioka K: Topical tacrolimus is effective for facial lesions of psoriasis. Acta Derm Venereol 2000;80:451.
31. Yamamoto T, Nishioka K: Topical tacrolimus: an effective therapy for facial psoriasis. Eur J Dermatol 2003;13:471-473.
32. Gardner SS, McKay M: Seborrhea, psoriasis and the papulosquamous dermatoses. Prim Care 1989;16:739-763.
33. Braza TJ, DiCarlo JB, Soon SL, McCall CO: Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br J Dermatol 2003;148:1242-1244.
34. Brownell I, Quan LT, Hsu S: Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol Online J 2003;9:13.
35. Crutchfield CE, 3rd: Pimecrolimus: a new treatment for seborrheic dermatitis. Cutis 2002;70:207-208.
36. Meshkinpour A, Sun J, Weinstein G: An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 2003;49:145-147.
37. Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, Katsambas A: Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol 2004;151:1071-1075.
38. Abe R, Shimizu T, Tsuji A, Matsumura T, Shimizu H: Severe refractory chronic actinic dermatitis successfully treated with tacrolimus ointment. Br J Dermatol 2002;147:1273-1275.
39. Evans AV, Palmer RA, Hawk JL: Erythrodermic chronic actinic dermatitis responding only to topical tacrolimus. Photodermatol Photoimmunol Photomed 2004;20:59-61.
40. Larangeira de Almeida H, Jr.: Successful treatment of chronic actinic dermatitis with topical pimecrolimus. Int J Dermatol 2005;44:343-344.
41. Uetsu N, Okamoto H, Fujii K, Doi R, Horio T: Treatment of chronic actinic dermatitis with tacrolimus ointment. J Am Acad Dermatol 2002;47:881-884.
42. Ogawa Y, Adachi A, Tomita Y: The successful use of topical tacrolimus treatment for a chronic actinic dermatitis patient with complications of idiopathic leukopenia. J Dermatol 2003;30:805-809.
43. Suga Y, Hashimoto Y, Matsuba S, Mizoguchi M, Ogawa H: Topical tacrolimus for chronic actinic dermatitis. J Am Acad Dermatol 2002;46:321-323.
44. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB: A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003;139:581-585.
45. Mayoral FA, Gonzalez C, Shah NS, Arciniegas C: Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 2003;207:322-323.
46. Walker SL, Kirby B, Chalmers RJ: The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol 2002;147:405-406.
47. de la Rosa Carrillo D, Christensen OB: Treatment of chronic discoid lupus erythematosus with topical tacrolimus. Acta Derm Venereol 2004;84:233-234.
48. Druke A, Gambichler T, Altmeyer P, Freitag M, Kreuter A: 0.1% Tacrolimus ointment in a patient with subacute cutaneous lupus erythematosus. J Dermatol Treat 2004;15:63-64.
49. Griffies JD, Mendelsohn CL, Rosenkrantz WS, Muse R, Boord MJ, Griffin CE: Topical 0.1% tacrolimus for the treatment of discoid lupus erythematosus and pemphigus erythematosus in dogs. J Am Anim Hosp Assoc 2004;40:29-41.
50. Kanekura T, Yoshii N, Terasaki K, Miyoshi H, Kanzaki T: Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 2003;148:353-356.
51. Zabawski E: Treatment of cutaneous lupus with Elidel. Dermatol Online J 2002;8:25.
52. Katoh N, Mihara H, Yasuno H: Cutaneous sarcoidosis successfully treated with topical tacrolimus. Br J Dermatol 2002;147:154-156.
53. Dissemond J, Schroter S, Franckson T, Herbig S, Goos M: Pimecrolimus in an adhesive ointment as a new treatment option for oral lichen planus. Br J Dermatol 2004;150:782-784.
54. Esquivel-Pedraza L, Fernandez-Cuevas L, Ortiz-Pedroza G, Reyes-Gutierrez E, Orozco-Topete R: Treatment of oral lichen planus with topical pimecrolimus 1% cream. Br J Dermatol 2004;150:771-773.
55. Goldstein AT, Marinoff SC, Christopher K: Pimecrolimus for the treatment of vulvar lichen sclerosus in a premenarchal girl. J Pediatr Adolesc Gynecol 2004;17:35-37.
56. Swift JC, Rees TD, Plemons JM, Hallmon WW, Wright JC: The effectiveness of 1% pimecrolimus cream in the treatment of oral erosive lichen planus. J Periodontol 2005;76:627-635.
57. Assmann T, Becker-Wegerich P, Grewe M, Megahed M, Ruzicka T: Tacrolimus ointment for the treatment of vulvar lichen sclerosus. J Am Acad Dermatol 2003;48:935-937.
58. Bohm M, Frieling U, Luger TA, Bonsmann G: Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol 2003;139:922-924.
59. Hodgson TA, Sahni N, Kaliakatsou F, Buchanan JA, Porter SR: Long-term efficacy and safety of topical tacrolimus in the management of ulcerative/erosive oral lichen planus. Eur J Dermatol 2003;13:466-470.
60. Kaliakatsou F, Hodgson TA, Lewsey JD, Hegarty AM, Murphy AG, Porter SR: Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol 2002;46:35-41.
61. Lener EV, Brieva J, Schachter M, West LE, West DP, el-Azhary RA: Successful treatment of erosive lichen planus with topical tacrolimus. Arch Dermatol 2001;137:419-422.
62. Morrison L, Kratochvil FJ, 3rd, Gorman A: An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol 2002;47:617-620.
63. Olivier V, Lacour JP, Mousnier A, Garraffo R, Monteil RA, Ortonne JP: Treatment of chronic erosive oral lichen planus with low concentrations of topical tacrolimus: an open prospective study. Arch Dermatol 2002;138:1335-1338.
64. Rozycki TW, Rogers RS, 3rd, Pittelkow MR, McEvoy MT, el-Azhary RA, Bruce AJ, Fiore JP, Davis MD: Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. J Am Acad Dermatol 2002;46:27-34.
65. Kameda G, Kramm C, Stege H, Hermsen D, Krutmann J, Niehues T: Unexpected high serum levels of tacrolimus after a single topical application in an infant. J Pediatr 2003;143:280.
66. Kawashima M, Nakagawa H, Ohtsuki M, Tamaki K, Ishibashi Y: Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet 1996;348:1240-1241.
67. Russell RK, Richardson N, Wilson DC: Systemic absorption with complications during topical tacrolimus treatment for orofacial Crohn disease. J Pediatr Gastroenterol Nutr 2001;32:207-208.
68. Soter NA, Fleischer AB, Jr., Webster GF, Monroe E, Lawrence I: Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001;44:S39-46.
69. Chu J, Bradley M, Marinkovich MP: Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. Arch Dermatol 2003;139:813-815.
70. Chuh AA: The application of topical tacrolimus in vesicular pemphigoid. Br J Dermatol 2004;150:622-623.
71. Ko MJ, Chu CY: Topical tacrolimus therapy for localized bullous pemphigoid. Br J Dermatol 2003;149:1079-1081.
72. Rabeni EJ, Cunningham NM: Effective treatment of Hailey-Hailey disease with topical tacrolimus. J Am Acad Dermatol 2002;47:797-798.
73. Sand C, Thomsen HK: Topical tacrolimus ointment is an effective therapy for Hailey-Hailey disease. Arch Dermatol 2003;139:1401-1402.
74. Umar SA, Bhattacharjee P, Brodell RT: Treatment of Hailey-Hailey disease with tacrolimus ointment and clobetasol propionate foam. J Drugs Dermatol 2004;3:200-203.
75. Ghislain PD, De Decker I, Lachapelle JM: Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum. Br J Dermatol 2004;150:1052-1053.
76. Khurrum Baig M, Marquez H, Nogueras JJ, Weiss EG, Wexner SD: Topical tacrolimus (FK506) in the treatment of recalcitrant parastomal pyoderma gangrenosum associated with Crohn's disease: report of two cases. Colorectal Dis 2004;6:250-253.
77. Vidal D, Alomar A: Successful treatment of periostomal pyoderma gangrenosum using topical tacrolimus. Br J Dermatol 2004;150:387-388.
78. Feldmann KA, Kunte C, Wollenberg A, Wolfe H: Is topical tacrolimus effective in alopecia areata universalis? Br J Dermatol 2002;147:1031-1032.
79. Freyschmidt-Paul P, Ziegler A, McElwee KJ, Happle R, Kissling S, Sundberg JP, Hoffmann R: Treatment of alopecia areata in C3H/HeJ mice with the topical immunosuppressant FK506 (Tacrolimus). Eur J Dermatol 2001;11:405-409.
80. Park SW, Kim JW, Wang HY: Topical tacrolimus (FK506): treatment failure in four cases of alopecia universalis. Acta Derm Venereol 2002;82:387-388.
81. Thiers BH: Topical tacrolimus: treatment failure in a patient with alopecia areata. Arch Dermatol 2000;136:124.
82. Mrowietz U, Graeber M, Brautigam M, Thurston M, Wagenaar A, Weidinger G, Christophers E: The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998;139:992-996.
83. Remitz A, Reitamo S, Erkko P, Granlund H, Lauerma AI: Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999;141:103-107.
84. Rappersberger K, Komar M, Ebelin ME, Scott G, Burtin P, Greig G, Kehren J, Chibout SD, Cordier A, Holter W, Richter L, Oberbauer R, Stuetz A, Wolff K: Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002;119:876-887.
85. Papp KA: Potential future therapies for psoriasis. Semin Cutan Med Surg 2005;24:58-63.
86. Scheinfeld N: The use of topical tacrolimus and pimecrolimus to treat psoriasis: a review. Dermatol Online J 2004;10:3.
87. Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR: Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol 2005;141:43-46.
88. Gottlieb AB, Griffiths CE, Ho VC, Lahfa M, Mrowietz U, Murrell DF, Ortonne JP, Todd G, Cherill R, Marks I, Emady-Azar S, Paul CF: Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br J Dermatol 2005;152:1219-1227.
89. Allen A, Siegfried E, Silverman R, Williams ML, Elias PM, Szabo SK, Korman NJ: Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001;137:747-750.
90. Oji V, Beljan G, Beier K, Traupe H, Luger TA: Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br J Dermatol 2005;153:1067-1068.
91. Rodriguez Garcia F, Fagundo Gonzalez E, Cabrera-Paz R, Rodriguez Martin M, Saez Rodriguez M, Martin-Neda F, Garcia Bustinduy M, Noda Cabrera A, Sanchez Gonzalez R: Generalized pustular psoriasis successfully treated with topical tacrolimus. Br J Dermatol 2005;152:587-588.
92. Kroft EB, Erceg A, Maimets K, Vissers W, van der Valk PG, van de Kerkhof PC: Tacrolimus ointment for the treatment of severe facial plaque psoriasis. J Eur Acad Dermatol Venereol 2005;19:249-251.
93. Price VH, Willey A, Chen BK: Topical tacrolimus in alopecia areata. J Am Acad Dermatol 2005;52:138-139.
94. Coskun B, Saral Y, Turgut D: Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 2005;15:88-91.
95. Prats Caelles I, Herranz Pinto P, de Ayala Casado EL, de Lucas Laguna R: Focal hypertrichosis during topical tacrolimus therapy for childhood vitiligo. Pediatr Dermatol 2005;22:86-87.
96. Ahn BK, Kim BD, Lee SJ, Lee SH: Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment. J Am Acad Dermatol 2005;52:532-533.
97. Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F: Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 2002;12:50-52.
98. Crawford KM, Russ B, Bostrom P: Pimecrolimus for treatment of acne rosacea. Skinmed 2005;4:147-150.
99. Chu CY: The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br J Dermatol 2005;152:396-399.
100. Hira K, Suga Y, Monma T, Mitsuishi K, Ogawa H: Tacrolimus ointment in the treatment of dirty neck lesions in atopic dermatitis. J Am Acad Dermatol 2005;52:720-722.
101. Tzung TY, Wu JC: Topical calcineurin inhibitors in treating Jessner's lymphocytic infiltration of the skin: report of a case. Br J Dermatol 2005;152:383-384.
102. Murphy CC, Greiner K, Plskova J, Duncan L, Frost NA, Forrester JV, Dick AD: Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005;123:634-641.
103. Joseph MA, Kaufman HE, Insler M: Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea 2005;24:417-420.
104. Chiba T, Isomura I, Suzuki A, Morita A: Topical tacrolimus therapy for pyoderma gangrenosum. J Dermatol 2005;32:199-203.
105. Deckers-Kocken JM, Pasmans SG: Successful tacrolimus (FK506) therapy in a child with pyoderma gangrenosum. Arch Dis Child 2005;90:531.
106. Meyer S, Burgdorff T, Szeimies RM, Vogt T, Landthaler M, Karrer S: Management of erosive lichen planus with topical tacrolimus and recurrence secondary to metoprolol. J Eur Acad Dermatol Venereol 2005;19:236-239.
107. Werchniak AE, Storm CA, Plunkett RW, Beutner EH, Dinulos JG: Treatment of pyostomatitis vegetans with topical tacrolimus. J Am Acad Dermatol 2005;52:722-723.
108. Rigopoulos D, Prantsidis A, Christofidou E, Ioannides D, Gregoriou S, Katsambas A: Pimecrolimus 1% cream in the treatment of disseminated granuloma annulare. Br J Dermatol 2005;152:1364-1365.
109. Schmook T, Kraft J, Benninghoff B, Nindl I, Roewert J, Ulrich C, Stockfleth E: Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus. Bone Marrow Transplant 2005;36:87-88.
110. Black RJ: Vulval eczema associated with propolis sensitization from topical therapies treated successfully with pimecrolimus cream. Clin Exp Dermatol 2005;30:91-92.
111. Sugita T, Tajima M, Ito T, Saito M, Tsuboi R, Nishikawa A: Antifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia species. J Clin Microbiol 2005;43:2824-2829.
112. Park CW, Lee BH, Lee CH: Tacrolimus reduces staphylococcal colonization on the skin in Korean atopic dermatitis patients. Drugs Exp Clin Res 2005;31:77-87.
113. Duque MI, Yosipovitch G, Fleischer AB, Jr, Willard J, Freedman BI: Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. J Am Acad Dermatol 2005;52:519-521.
114. Aguilar-Bernier M, Bassas-Vila J, Sanz-Munoz C, Miranda-Romero A: Successful treatment of pruritus with topical tacrolimus in a patient with primary biliary cirrhosis. Br J Dermatol 2005;152:808-809.
115. El-Dars LD, Statham BN, Blackford S, Williams N: Lymphocytoma cutis treated with topical tacrolimus. Clin Exp Dermatol 2005;30:305-307.
116. Clayton TH, Harrison PV: Successful treatment of chronic ulcerated necrobiosis lipoidica with 0.1% topical tacrolimus ointment. Br J Dermatol 2005;152:581-582.
117. Kessel A, Bamberger E, Toubi E: Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open-label prospective study. J Am Acad Dermatol 2005;52:145-148.